Ribocil C Antibiotic Compounds for Gram-Negative Membrane Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective antibiotics against Gram-negative bacteria due to the challenges posed by their outer membrane structure, which limits the diffusion of small molecules, and existing strategies based on molecular weight and polarity have not led to broad-spectrum antibiotics.
Innovation Solution
Development of novel compounds, such as Debio-1452 and its derivatives, which are designed to overcome the outer membrane barrier by targeting specific cellular pathways, specifically the FabI enzyme, thereby achieving effective Gram-negative activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If small molecules are used to penetrate the outer membrane, then they can enter the bacterial cell, but they are restricted by the narrow constriction zone of porins to molecules with molecular weight less than 600 Da
Solution Approach 1:
The patent changes the physicochemical parameters of the antibiotic molecules, specifically optimizing molecular weight to be less than 600 Da and adjusting polarity (ClogD7.4) to enhance passive diffusion through porin channels. This allows the molecules to overcome the outer membrane barrier while maintaining cellular accumulation capability.
2Ease of operation
If small molecules cross the outer membrane via porins, then they can enter the cell, but efflux pumps actively pump them out, reducing intracellular accumulation
Solution Approach 1:
The patent optimizes molecular parameters (weight and polarity) to create a balance where the rate of passive diffusion through porins exceeds the rate of efflux pump export. This net positive accumulation allows sufficient intracellular concentration to achieve antimicrobial activity.
3Measurement precision
If retrospective analyses show that Gram-negative active compounds are small and polar, then these properties seem necessary, but many compounds meeting these criteria are inactive, suggesting these properties do not fully encompass the determinants for accumulation
Solution Approach 1:
The patent employs a feedback loop combining in silico predictions of passive diffusion rates with experimental whole-cell accumulation data. This iterative process refines the predictive models, allowing identification of additional determinants beyond molecular weight and polarity that influence cellular accumulation.
Solution Approach 2:
The patent introduces in silico calculated passive diffusion rates as an intermediary parameter that mediates between molecular structure (weight, polarity) and experimental accumulation data. This intermediary enables more accurate prediction by capturing the net effect of membrane permeability and efflux in a computable form.
4Adaptability or versatility
If new classes of antibiotics active against Gram-negative bacteria are discovered, then treatment options expand, but no new class has been introduced since quinolones in 1968
Solution Approach 1:
The patent uses a systematic approach to convert existing Gram-positive antibiotics into Gram-negative active compounds by applying the learned rules (weight < 600 Da, optimized polarity) to modify known structures. This copying and adaptation strategy generates novel Gram-negative actives from established molecular frameworks.
Solution Approach 2:
The patent applies parameter changes to existing antibiotic molecules, specifically reducing molecular weight and adjusting polarity, to transform them from Gram-positive only activity to broad-spectrum Gram-negative activity. This chemical modification strategy creates new effective agents without requiring entirely new molecular classes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel compounds demonstrate significant antimicrobial activity against Gram-negative pathogens, including Enterobacteriaceae clinical isolates, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli, showing efficacy in both in vitro and in vivo models, including mouse sepsis and pneumonia models.
Implementation Method 1
In order to accumulate to a level sufficient for activity, small molecules typically must cross the outer-membrane via channel proteins called porins, which are narrow β-barrels lined with charged amino acids that serve as selective gateways to entry for many small molecule antibiotics.
Data Source
AI summary
Disclosed herein are antibacterial compounds that accumulate in Gram-negative bacteria, methods of preparing the compounds, and methods of using the compounds to inhibit or kill microbes, and methods of treating microbial infections, such as Gram-negative bacterial infections. Compounds selected for conversion to potential Gram-negative antibacterial compounds were identified based on compounds having low globularity and low flexibility. Amine substituents were then strategically added to the selected compounds to provide compounds having antibacterial activity against Gram-negative bacteria.